Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

Fig. 3

Forest plots demonstrating the multivariate analysis of prognostic factors for DFS and OS, including the interaction between MMR protein status and primary tumor location. MMR protein status significantly interacted with primary site only for OS and not for DFS. Position at the right side of the bar indicates adverse prognostic significance, whereas the opposite is consistent with favorable outcome. HR, hazard ratio; CI, confidence interval; DFS, disease-free survival; OS, overall survival; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us